Phase II Open Label,Randomized Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of an Anti-Inflammatory Therapeutic Antibody(CV-18C3)in Reducing Restenosis in Patients Undergoing Percutaneous Femoro-popliteal Revascularization.
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2016
Price : $35 *
At a glance
- Drugs Bermekimab (Primary)
- Indications Vascular restenosis
- Focus Adverse reactions
- Sponsors XBiotech
- 02 Oct 2015 Results published in the Journal of Vascular Surgery, according to a XBiotech media release.
- 02 Oct 2015 Results published in a XBiotech media release.
- 26 Jun 2014 New trial record